摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-Chloro-3,4,5,6-tetrahydro-2,6-methano-2-methyl-4-oxo-1-benzoxocin | 78345-16-1

中文名称
——
中文别名
——
英文名称
7-Chloro-3,4,5,6-tetrahydro-2,6-methano-2-methyl-4-oxo-1-benzoxocin
英文别名
3-Chloro-9-methyl-8-oxatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-11-one
7-Chloro-3,4,5,6-tetrahydro-2,6-methano-2-methyl-4-oxo-1-benzoxocin化学式
CAS
78345-16-1
化学式
C13H13ClO2
mdl
——
分子量
236.698
InChiKey
HJOLQMAFRJKZBC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    16
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    7-Chloro-3,4,5,6-tetrahydro-2,6-methano-2-methyl-4-oxo-1-benzoxocin甲氧基胺盐酸盐吡啶 作用下, 以 乙醇氯仿 为溶剂, 生成 7-Chloro-3,4,5,6-tetrahydro-2,6-methano-2-methyl-4-oxo-1-benzoxocin O-Methyloxime
    参考文献:
    名称:
    Benzoxocin derivatives having anxiolytic and anti-convulsant activities
    摘要:
    揭示了一般式为##STR1##的化合物,其中R.sub.1代表氢原子或C.sub.1-4烷基或C.sub.2-4烯基基团,或基团COANH.sub.2,CSANH.sub.2,或COANHCOCH.sub.2 NH.sub.2,其中A是亚甲基,可选择地被C.sub.1-3烷基基团取代;R.sub.2代表氢原子或C.sub.1-4烷基基团;或NR.sub.1 R.sub.2形成哌啶基、哌嗪基或N-甲基哌嗪基;R.sub.3代表C.sub.1-4烷基或苄基;R.sub.4代表氢原子或卤素原子;R.sub.5代表氢原子或C.sub.1-4烷基或C.sub.1-4烷氧基团,但R.sub.4和R.sub.5中的一个为氢原子,其生理上可接受的盐和生物前体。这些化合物对中枢神经系统产生影响,特别表现出抗焦虑和抗惊厥活性。这些化合物可以与药用可接受的载体或稀释剂配制,以常规方式进行给药。
    公开号:
    US04315006A1
点击查看最新优质反应信息

文献信息

  • 3,4,5,6-Tetrahydro-2,6-methano-4 beta-amino-1-benzoxocin derivatives, process for their preparation and compositions containing them
    申请人:GLAXO GROUP LIMITED
    公开号:EP0024843A1
    公开(公告)日:1981-03-11
    Compounds are disclosed of general formula wherein R1 represents a hydrogen atom or C1-4 alkyl or C2-4 alkenyl group, or the group COANH2, CSANH2, or COANHCOCH2NH2 in which A is methylene optionally substituted by a C1-3 alkyl group; and R2 represents a hydrogen atom or a C1-4 alkyl group; or NR1R2 forms a piperidino, piperazino or N-methylpiperazino group; R3 represents a C1-4 alkyl group or a benzyl group; R4 represents a hydrogen or halogen atom; and R5 represents a hydrogen atom or a C1-4 alkyl or C1-4 alkoxy group, with the proviso that one of R4 and Rs is a hydrogen atom and physiologically acceptable salts and bioprecursors thereof. The compounds exert efforts on the central nervous system and, in particular exhibit anxiolytic and anti-convulsant activity. The compounds may be formulated with pharmaceutically acceptable carriers or diluents for administration in conventional manner.
    公开了通式如下的化合物 式中 R1代表氢原子或C1-4烷基或C2-4烯基,或基团COANH2、CSANH2或COANHCOCH2NH2,其中A是可选被C1-3烷基取代的亚甲基;R2代表氢原子或C1-4烷基;或NR1R2形成哌啶基、哌嗪基或N-甲基哌嗪基; R3 代表 C1-4 烷基或苄基; R4 代表氢原子或卤素原子;以及 R5 代表氢原子或 C1-4 烷基或 C1-4 烷氧基,但 R4 和 Rs 之一为氢原子,以及其生理上可接受的盐和生物前体。 这些化合物可作用于中枢神经系统,尤其具有抗焦虑和抗惊厥活性。这些化合物可与药学上可接受的载体或稀释剂一起配制,以常规方式给药。
  • US4315006A
    申请人:——
    公开号:US4315006A
    公开(公告)日:1982-02-09
  • Benzoxocin derivatives having anxiolytic and anti-convulsant activities
    申请人:Glaxo Group Limited
    公开号:US04315006A1
    公开(公告)日:1982-02-09
    Compounds are disclosed of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom or C.sub.1-4 alkyl or C.sub.2-4 alkenyl group, or the group COANH.sub.2, CSANH.sub.2, or COANHCOCH.sub.2 NH.sub.2 in which A is methylene optionally substituted by a C.sub.1-3 alkyl group; and R.sub.2 represents a hydrogen atom or a C.sub.1-4 alkyl group; or NR.sub.1 R.sub.2 forms a piperidino, piperazino or N-methylpiperazino group; R.sub.3 represents a C.sub.1-4 alkyl group or a benzyl group; R.sub.4 represents a hydrogen or halogen atom; and R.sub.5 represents a hydrogen atom or a C.sub.1-4 alkyl or C.sub.1-4 alkoxy group, with the proviso that one of R.sub.4 and R.sub.5 is a hydrogen atom and physiologically acceptable salts and bioprecursors thereof. The compounds exert effects on the central nervous system and, in particular exhibit anxiolytic and anti-convulsant activity. The compounds may be formulated with pharmaceutically acceptable carriers or diluents for administration in conventional manner.
    揭示了一般式为##STR1##的化合物,其中R.sub.1代表氢原子或C.sub.1-4烷基或C.sub.2-4烯基基团,或基团COANH.sub.2,CSANH.sub.2,或COANHCOCH.sub.2 NH.sub.2,其中A是亚甲基,可选择地被C.sub.1-3烷基基团取代;R.sub.2代表氢原子或C.sub.1-4烷基基团;或NR.sub.1 R.sub.2形成哌啶基、哌嗪基或N-甲基哌嗪基;R.sub.3代表C.sub.1-4烷基或苄基;R.sub.4代表氢原子或卤素原子;R.sub.5代表氢原子或C.sub.1-4烷基或C.sub.1-4烷氧基团,但R.sub.4和R.sub.5中的一个为氢原子,其生理上可接受的盐和生物前体。这些化合物对中枢神经系统产生影响,特别表现出抗焦虑和抗惊厥活性。这些化合物可以与药用可接受的载体或稀释剂配制,以常规方式进行给药。
查看更多